Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

With Genetic Testing Results, More May Be Better

Kathryn Doyle  |  January 26, 2016

In the past, experts have been concerned about how much genetic information to share with patients who are otherwise healthy, based on the potential for misunderstanding or making serious health choices based on their genes, senior author Dr. Robert C. Green of Brigham and Women’s Hospital and Harvard Medical School in Boston told Reuters Health by phone.

“There’s an inaccurate stereotype that DNA is destiny,” Green said.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Genetic sequencing, which used to cost three billion dollars, now costs about $1,000, he said, or about 923 euros.

“People who choose to get (Alzheimer’s risk) information actually do very well, even though there’s no treatment or prevention,” he said. “But if you start off wanting to know Alzheimer’s risk information, and get surprised with information you completely didn’t expect, how will you react?”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“This mimics the way a lot of genetic testing is going,” Green said. “You might get tested for a heart problem and might find out you have a risk for cancer. Is it ethical to surprise people with that?”

It would be risky to generalize the results of this study to every kind of genetic risk, he said.

“If we’re talking about setting up approaches for the general population, I think emphasizing the results that we are confident about and that we can do something about should (be) put at the top of the list,” said Dr. Michael F. Murray of the Geisinger Health System in Forty Fort, Pennsylvania.

“If the question is, ‘Should we go in and find that some people might be at risk for Alzheimer’s disease but they can’t do anything about it, or should we look at breast cancer risk, which they can do something about,'” most people would choose to learn about their breast cancer risk, Murray, who wrote an editorial accompanying the new results, told Reuters Health by phone.

A healthy person who is very motivated and has the resources may still want to know their genetic risk for Alzheimer’s, and should be able to find out, but until a treatment or way to prevent the disease is developed, it’s not a test that should be done for the general population, Murray said.

Page: 1 2 | Single Page
Share: 

Filed under:Practice SupportTechnology Tagged with:Alzheimer's DiseaseGenetic researchgenetic riskgenetic testgeneticsTesting

Related Articles

    7 Tools to Identify Depression

    August 1, 2014

    Why screening for depressive symptoms in patients with arthritis is needed

    Exploring Kawasaki Disease

    April 2, 2014

    New epidemiologic data, clinical studies have shed light on diagnosis, treatments, patient outcomes for this childhood disease, but etiology is still unknown

    Depression in Rheumatoid Arthritis

    November 1, 2012

    Examining the psychological and health-related comorbidities of rheumatoid arthritis patients with depression

    Anxiety Is an Independent Risk Factor for Bone Fractures

    November 18, 2018

    Higher anxiety levels in postmenopausal women may put them at increased risk of fracture and should be considered when assessing a woman’s risk of osteoporosis as well. This is the conclusion of a study recently published in the journal Menopause that looked at the role of anxiety in bone health.1 Specifically, the study examined the…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences